GlassScriptPhysician profile
Beverly Boykin Thomas
NPI 1790752442
$3,809.48
in general payments reported to CMS, 2019-2025
28 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $334 · 2023: $243 · 2024: $970 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,231.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $401.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $310.85 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $308.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.41 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $240.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.63 | 2019-2025 | Jardiance |
| Amgen INC. | $214.49 | 2019-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $118.23 | 2019 | |
| Exact Sciences Corporation | $93.94 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.04 | 2019-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $71.95 | 2019 | |
| Sumitomo Pharma America, INC. | $62.20 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $59.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.93 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.03 | 2023-2024 | Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $49.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.20 | 2025 | Zoryve |
| Shield Therapeutics INC | $41.48 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.84 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $33.11 | 2024-2025 | Voquezna |
| Dexcom, INC. | $30.45 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $24.29 | 2024 | |
| Axsome Therapeutics, INC. | $23.69 | 2025 | Symbravo |
| Abbott Laboratories | $19.17 | 2019 | |
| Shire North American Group INC | $16.38 | 2019 | |
| Amarin Pharma, INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.